Cabaletta Bio (CABA)
Develops engineered T-cell therapies for autoimmune disease, prioritizing rese-cel.
$2.50
After hours+0.00 (+0.20%)
At close$2.50(+1.42%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 93.04% | 157.75M shares | |
|---|---|---|---|
| 151 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.14% | 244.2K shares | |
| 7 holders · as of Jan 21, 2026 | |||
| Other | ≈ 6.82% | 11.55M shares | |
| remainder | |||
169.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
151 holders · 157.75M shares · 54 new positions · 107 increased · 22 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jennison Associates LLC | 20.03M | 11.82% | +11.06M | Aug 3, 2026 |
| T. Rowe Price Investment Management, Inc. | 18.87M | 11.13% | +7.79M | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 17.24M | 10.17% | +7.56M | Aug 14, 2026 |
| BlackRock, Inc. | 10.75M | 6.34% | +8.38M | Aug 7, 2026 |
| Adage Capital Partners GP, L.L.C. | 9.17M | 5.41% | +345.0K | Aug 14, 2026 |
| State Street Corp | 7.84M | 4.62% | +7.37M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 7.23M | 4.26% | +3.20M | Aug 13, 2026 |
| Cormorant Asset Management, LP | 5.00M | 2.95% | −500.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Prudential Financial Inc | 11.40% | 24.27M | 13G | Jun 5, 2026 |
| Jennison Associates LLC | 11.40% | 24.27M | 13G | Jun 4, 2026 |
| T. Rowe Price Investment Management, Inc. | 10.20% | 9.86M | 13G | Feb 17, 2026 |
| Bain Capital Life Sciences Opportunities III, LP | 9.99% | 9.68M | 13G | Aug 14, 2025 |
| Adage Capital Management, L.P. | 9.99% | 9.00M | 13G | Aug 12, 2025 |
| Cormorant Asset Management, LP | 9.03% | 10.50M | 13G | May 15, 2026 |
| BlackRock, Inc. | 5.90% | 9.61M | 13G | Jul 27, 2026 |
| Norges Bank | 5.38% | 8.78M | 13G | Aug 12, 2026 |
| Millennium Management LLC | 5.30% | 5.13M | 13G | Feb 18, 2026 |
| Vanguard Capital Management | 5.08% | 8.30M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 21, 2026 | Michael Gerardofficer: General Counsel | Purchase | 6,600 | $2.27 | 6,600 |
| Jan 21, 2026 | Mark Simondirector | Purchase | 11,061 | $2.28 | 147,205 |
| Jan 21, 2026 | Steven Nichtbergerdirector, officer: President & CEO | Purchase | 45,000 | $2.24 | 1,031,483 |
| Jan 21, 2026 | Catherine Bollarddirector | Purchase | 4,405 | $2.27 | 5,405 |
| Jan 21, 2026 | Steve Gavelofficer: Chief Commercial Officer | Purchase | 22,170 | $2.27 | 22,170 |
| Jan 21, 2026 | Shawn Tomasellodirector | Purchase | 22,725 | $2.21 | 22,725 |
| Jan 21, 2026 | Gwendolyn Binderofficer: President, Science & Tech. | Purchase | 11,312 | $2.19 | 31,312 |
| Jan 21, 2026 | David J. Changofficer: Chief Medical Officer | Purchase | 8,800 | $2.26 | 8,800 |
House and Senate disclosures
Not reported.